AbCellera Biologics(ABCL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ABCL AbCellera Biologics

Trading 10-29 13:47:21 EDT

13.17

-0.47

-3.45%

High13.86	Low13.17	Vol1.61M
Open13.41	D1 Closing13.64	Amplitude5.10%
Mkt Cap4.27B	Tradable Cap2.91B	Total Shares324.00M
T/O21.84M	T/O Rate0.73%	Tradable Shares221.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ABCL","market":"US","secType":"STK","nameCN":"AbCellera Biologics","latestPrice":13.17,"timestamp":1793296033973,"preClose":13.64,"halted":0,"volume":1611969,"delay":0,"changeRate":-0.03445747800586515,"floatShares":221000000,"shares":324000000,"eps":-0.545545,"marketStatus":"Trading","change":-0.47,"latestTime":"10-29 13:47:21 EDT","open":13.41,"high":13.86,"low":13.165,"amount":21841922.034959998,"amplitude":0.050953,"askPrice":13.17,"askSize":220,"bidPrice":13.16,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.545545,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1793304000000},"marketStatusCode":2,"adr":0,"listingDate":1607662800000,"exchange":"NASDAQ","adjPreClose":13.64,"preHourTrading":{"tag":"盘前","latestPrice":13.35,"preClose":13.64,"latestTime":"09:25 EDT","volume":18700,"amount":250913.58930000002,"timestamp":1793280353198,"change":-0.29,"changeRate":-0.021261,"amplitude":0.040982},"postHourTrading":{"tag":"盘后","latestPrice":13.55,"preClose":13.64,"latestTime":"19:58 EDT","volume":56302,"amount":765364.2516,"timestamp":1793231926879,"change":-0.09,"changeRate":-0.006598,"amplitude":0.019985},"volumeRatio":0.722325,"impliedVol":0.857,"impliedVolPercentile":0.2151},"requestUrl":"/m/hq/s/ABCL","defaultTab":"news","newsList":[{"id":"2677299658","title":"AbCellera Presents at Stifel and Jefferies Healthcare Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2677299658","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677299658?lang=en_us&edition=fundamental","pubTime":"2026-10-23 04:05","pubTimestamp":1792699556,"startTime":"0","endTime":"0","summary":"AbCellera Presents at Stifel and Jefferies Healthcare ConferencesAbCellera will present at the Stifel Healthcare Conference on November 11, 2026.Its next presentation is at the Jefferies Global Health","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261022:nNDL1TBjWn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL","BK4121","BK4127","BK4535","SF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675331688","title":"After AbCellera Biologics' 125% Climb, The Story Has Changed","url":"https://stock-news.laohu8.com/highlight/detail?id=2675331688","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675331688?lang=en_us&edition=fundamental","pubTime":"2026-10-13 14:22","pubTimestamp":1791872562,"startTime":"0","endTime":"0","summary":"If you only glanced at AbCellera Biologics during this stretch, the headlines might have felt mixed. For AbCellera Biologics shareholders, the return over the past year was 124.8%, including dividends. That surge arrived alongside revenue that moved from US$17.084 million in Q2 2025 to US$4.05 million in Q2 2026 and a wider quarterly loss. If you had been deciding back in October 2025, you might have asked what mattered more: the clinical and partnership story, or the financial...","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9551728-choice2-card/1789016329041","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9551728-choice2-card/1789016329041"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/after-abcellera-biologics-125-climb-the-story-has-changed","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/after-abcellera-biologics-125-climb-the-story-has-changed","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4535","BK4121","ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675801609","title":"AbCellera Biologics' ABCL635 Seen With Best-in-Class Potential in Menopause, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2675801609","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675801609?lang=en_us&edition=fundamental","pubTime":"2026-10-13 00:55","pubTimestamp":1791824137,"startTime":"0","endTime":"0","summary":"AbCellera Biologics  ABCL635 could capture a greater share of a larger menopause market than investors currently anticipate, UBS Securities said.The brokerage said in a Sunday note that the experimental hot flash therapy has best-in-class potential if its phase 2 efficacy and safety profile holds up in larger studies, and that once-monthly dosing and the potential to avoid routine liver monitoring could make it a preferred option and an attractive direct-to-consumer product.The investment firm said oncology-associated hot flashes offer additional value, viewing the indication as relatively de-risked given the shared biology with menopause-related symptoms and Lynkuet's Oasis-4 study. UBS also highlighted ABCL635's phase 2 12-week follow-up data, expected in late 2026 or early 2027, as a key catalyst.UBS initiated coverage of the company with a buy rating and an $18 price target.Price: 12.78, Change: +0.23, Percent Change: +1.83","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ABCL","BK4121","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674808763","title":"AbCellera Biologics Initiated at Buy by UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2674808763","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674808763?lang=en_us&edition=fundamental","pubTime":"2026-10-12 21:32","pubTimestamp":1791811920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ABCL/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL","BK4121","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674872653","title":"UBS Initiates AbCellera Biologics at Buy With $18 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2674872653","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674872653?lang=en_us&edition=fundamental","pubTime":"2026-10-12 19:35","pubTimestamp":1791804926,"startTime":"0","endTime":"0","summary":"AbCellera Biologics (ABCL) has an average rating of buy and mean price target of $16.82, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674844958","title":"AbCellera initiated with a Buy at UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2674844958","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674844958?lang=en_us&edition=fundamental","pubTime":"2026-10-12 07:35","pubTimestamp":1791761706,"startTime":"0","endTime":"0","summary":"UBS initiated coverage of AbCellera (ABCL) with a Buy rating and $18 price target The firm believes ABCL635 is a “potentially transformative therap...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abcellera-initiated-with-a-buy-at-ubs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abcellera-initiated-with-a-buy-at-ubs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABCL","BK4535","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674863398","title":"AbCellera to Present Phase 1/2 ABCL635 Data at Menopause Society Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2674863398","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674863398?lang=en_us&edition=fundamental","pubTime":"2026-10-09 23:28","pubTimestamp":1791559733,"startTime":"0","endTime":"0","summary":"AbCellera Biologics  said late Thursday it will present phase 1/2 data on ABCL635, its investigational antibody treatment for menopause-related hot flashes, at The Menopause Society's 2026 annual meeting in San Diego.The presentation will include safety, pharmacokinetic, pharmacodynamic and efficacy data, including new safety results from the phase 1 multiple ascending dose study and new patient-reported outcomes from the phase 2 trial.ABCL635 is being evaluated as a non-hormonal, long-acting treatment for moderate-to-severe vasomotor symptoms associated with menopause, the biotechnology company said.Shares of AbCellera Biologics were up more than 4% in Friday trading.Price: 12.60, Change: +0.58, Percent Change: +4.83","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ABCL","BK4535","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674006810","title":"AbCellera to present Phase 1/2 data for ABCL635 at TMS 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2674006810","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674006810?lang=en_us&edition=fundamental","pubTime":"2026-10-09 04:11","pubTimestamp":1791490270,"startTime":"0","endTime":"0","summary":"AbCellera (ABCL) “announced an upcoming poster presentation of Phase 1/2 data on ABCL635 at The Menopause Society’s 2026 Annual Meeting, to be held...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abcellera-to-present-phase-1-2-data-for-abcl635-at-tms-2026-annual-meeting-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abcellera-to-present-phase-1-2-data-for-abcl635-at-tms-2026-annual-meeting-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABCL","BK4121","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672644487","title":"Press Release: AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2672644487","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672644487?lang=en_us&edition=fundamental","pubTime":"2026-10-02 04:14","pubTimestamp":1790885640,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia--(BUSINESS WIRE)--October 01, 2026--AbCellera (Nasdaq: ABCL) will announce its third quarter 2026 financial results on Monday, November 9, 2026, and hold an earnings confer","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4121","ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672764995","title":"AbCellera Schedules Quarterly Results Release, Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2672764995","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672764995?lang=en_us&edition=fundamental","pubTime":"2026-10-02 04:05","pubTimestamp":1790885119,"startTime":"0","endTime":"0","summary":"AbCellera schedules quarterly results release, earnings callAbCellera will release third-quarter 2026 financial results on Nov. 9, 2026.Earnings conference call set for Nov. 9, 2026 at 3:00 p.m. PT, 5","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDL7CrkLy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ABCL","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671292244","title":"AbCellera Biologics call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2671292244","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671292244?lang=en_us&edition=fundamental","pubTime":"2026-09-30 03:05","pubTimestamp":1790708710,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in AbCellera (ABCL) Biologics with 8,557 calls trading, 3x expected, and implied vol increasing over 1 point to 92.67%...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abcellera-biologics-call-volume-above-normal-and-directionally-bullish-thefly-news-7?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abcellera-biologics-call-volume-above-normal-and-directionally-bullish-thefly-news-7?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","ABCL","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671218947","title":"JPMorgan Initiates AbCellera Biologics at Overweight With $17 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2671218947","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671218947?lang=en_us&edition=fundamental","pubTime":"2026-09-29 17:53","pubTimestamp":1790675636,"startTime":"0","endTime":"0","summary":"AbCellera Biologics (ABCL) has an average rating of buy and mean price target of $16.70, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ABCL","PGF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671297157","title":"Abcellera Biologics Inc. : JP Morgan Initiates Coverage with Overweight Rating; Target Price $17","url":"https://stock-news.laohu8.com/highlight/detail?id=2671297157","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671297157?lang=en_us&edition=fundamental","pubTime":"2026-09-29 17:03","pubTimestamp":1790672608,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nFWN45L0B1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ABCL","BK4121","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670404312","title":"JonesTrading Sticks to Their Buy Rating for AbCellera Biologics (ABCL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2670404312","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670404312?lang=en_us&edition=fundamental","pubTime":"2026-09-28 05:55","pubTimestamp":1790546117,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Debanjana Chatterjee reiterated a Buy rating on AbCellera Biologics today and set a price target of $25.00. Chatterjee covers ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jonestrading-sticks-to-their-buy-rating-for-abcellera-biologics-abcl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jonestrading-sticks-to-their-buy-rating-for-abcellera-biologics-abcl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669602024","title":"AbCellera Biologics Price Target Announced at $13.00/Share by Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2669602024","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669602024?lang=en_us&edition=fundamental","pubTime":"2026-09-24 20:12","pubTimestamp":1790251920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ABCL/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669460679","title":"AbCellera Biologics (ABCL) Receives a Hold from Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2669460679","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669460679?lang=en_us&edition=fundamental","pubTime":"2026-09-24 19:45","pubTimestamp":1790250326,"startTime":"0","endTime":"0","summary":"Goldman Sachs analyst Andrea Newkirk resumed coverage with a Hold rating on AbCellera Biologics today and set a price target of $13.00. According t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/abcellera-biologics-abcl-receives-a-hold-from-goldman-sachs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/abcellera-biologics-abcl-receives-a-hold-from-goldman-sachs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","LU0868494708.USD","LU2471134952.CNY","GSX","IE0002270589.USD","IE0034235188.USD","BK4533","LU0345770308.USD","LU0742534661.SGD","LU1894683348.USD","LU1668664300.SGD","LU0048573561.USD","LU1868837136.USD","LU2265009873.SGD","LU2237443895.HKD","LU1868836757.USD","BK4585","BK4550","LU2237443382.USD","BK4127","LU1144417596.USD","LU2471134796.USD","IE00BSNM7G36.USD","LU0868494617.USD","LU0251131958.USD","LU1868837300.USD","LU0096364046.USD","IE0004086264.USD","BK4535","BK4504","LU0251142724.SGD","LU1894683264.USD","LU1804176565.USD","LU2471134523.USD","IE00B19Z3B42.SGD","BK4516","BK4552","IE0004091025.USD","IE00B19Z3581.USD","LU2237443465.HKD","LU2237443622.USD","ABCL","LU0210536198.USD","LU2471134879.HKD","LU2237438978.USD","LU1868836591.USD","LU2896262040.SGD","LU1791807156.HKD","BK4588","LU2750360641.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669169510","title":"Pharma Sector Doubles Down on AI to Slash Costs, Timelines","url":"https://stock-news.laohu8.com/highlight/detail?id=2669169510","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669169510?lang=en_us&edition=fundamental","pubTime":"2026-09-21 21:50","pubTimestamp":1789998651,"startTime":"0","endTime":"0","summary":"FACTBOX-Pharma sector doubles down on AI to slash costs, timelinesSept 21 (Reuters)-Pharmaceutical companies are increasingly turning to artificial intelligence to accelerate research and development,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nL4N45D0WW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN.UK","NVDQ","ABCL","KVUE","NVDS","NVDU","RSPS","NVDD","HEAL","03165","NVD","NVDA","FTEC","ROM","MRK","JGRO","NVDY","ILMN","NVDG","NVDL","TRUH","PAWZ","ILDR","VHT","TTXU","TMO","PFE","TYLG","INCY","NVII","NVDX","OZEM","RNAM","GOOGL","ANV","BMED","BMY","TMED","KD","IQV","VGT","LH","VT","VOX","ARTY","ABBV","MSFT","TTEQ","TEK","NULC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668966649","title":"AbCellera Biologics call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2668966649","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668966649?lang=en_us&edition=fundamental","pubTime":"2026-09-17 23:45","pubTimestamp":1789659911,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in AbCellera (ABCL) Biologics with 9,247 calls trading, 4x expected, and implied vol increasing over 10 points to 88.1...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abcellera-biologics-call-volume-above-normal-and-directionally-bullish-thefly-news-6?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abcellera-biologics-call-volume-above-normal-and-directionally-bullish-thefly-news-6?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","ABCL","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668337689","title":"AbCellera to present Phase 2 Data for ABCL635 at IMS Congress on Menopause","url":"https://stock-news.laohu8.com/highlight/detail?id=2668337689","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668337689?lang=en_us&edition=fundamental","pubTime":"2026-09-17 04:10","pubTimestamp":1789589409,"startTime":"0","endTime":"0","summary":"AbCellera (ABCL) “announced an upcoming oral presentation of Phase 2 data on ABCL635 at the International Menopause Society 20th World Congress on ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abcellera-to-present-phase-2-data-for-abcl635-at-ims-congress-on-menopause-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abcellera-to-present-phase-2-data-for-abcl635-at-ims-congress-on-menopause-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","BK4121","ABCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668331669","title":"AbCellera to Present Phase 2 Abcl635 Data for Menopause Hot Flashes at IMS World Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2668331669","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668331669?lang=en_us&edition=fundamental","pubTime":"2026-09-17 04:06","pubTimestamp":1789589166,"startTime":"0","endTime":"0","summary":"AbCellera to present Phase 2 ABCL635 data for menopause hot flashes at IMS World Congress 2026Abcellera flagged upcoming Phase 2 data for ABCL635, a non-hormonal antibody for menopausal hot flashes, a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nNDL4c4PXN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL","BK4535","BK4121"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abcellera.com","stockEarnings":[{"period":"1week","weight":0.1144},{"period":"1month","weight":-0.0201},{"period":"3month","weight":1.3972},{"period":"6month","weight":2.079},{"period":"1year","weight":1.4227},{"period":"ytd","weight":2.9883}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":0.0088},{"period":"3month","weight":0.0413},{"period":"6month","weight":0.0717},{"period":"1year","weight":0.1241},{"period":"ytd","weight":0.1326}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.002724},{"month":2,"riseRate":0,"avgChangeRate":-0.119779},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.059327},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.055905},{"month":5,"riseRate":0.666667,"avgChangeRate":0.054331},{"month":6,"riseRate":0.5,"avgChangeRate":0.144975},{"month":7,"riseRate":0.5,"avgChangeRate":-0.006532},{"month":8,"riseRate":0.5,"avgChangeRate":0.100971},{"month":9,"riseRate":0.666667,"avgChangeRate":0.075704},{"month":10,"riseRate":0.5,"avgChangeRate":-0.006361},{"month":11,"riseRate":0.6,"avgChangeRate":-0.007841},{"month":12,"riseRate":0.2,"avgChangeRate":-0.030878}],"exchange":"NASDAQ","name":"AbCellera Biologics","nameEN":"AbCellera Biologics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AbCellera Biologics(ABCL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest AbCellera Biologics(ABCL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"AbCellera Biologics,ABCL,AbCellera Biologics股票,AbCellera Biologics股票老虎,AbCellera Biologics股票老虎国际,AbCellera Biologics行情,AbCellera Biologics股票行情,AbCellera Biologics股价,AbCellera Biologics股市,AbCellera Biologics股票价格,AbCellera Biologics股票交易,AbCellera Biologics股票购买,AbCellera Biologics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AbCellera Biologics(ABCL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest AbCellera Biologics(ABCL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}